Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Total Current Liabilities (2021 - 2025)

Prime Medicine (PRME) has disclosed Total Current Liabilities for 5 consecutive years, with $37.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 1.35% year-over-year to $37.4 million, compared with a TTM value of $37.4 million through Dec 2025, down 1.35%, and an annual FY2025 reading of $37.4 million, down 1.35% over the prior year.
  • Total Current Liabilities was $37.4 million for Q4 2025 at Prime Medicine, up from $35.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $58.0 million in Q4 2021 and bottomed at $20.7 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $35.4 million, with a median of $34.7 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities tumbled 53.93% in 2022, then surged 111.21% in 2023.
  • Year by year, Total Current Liabilities stood at $58.0 million in 2021, then crashed by 53.93% to $26.7 million in 2022, then soared by 111.21% to $56.4 million in 2023, then plummeted by 32.72% to $38.0 million in 2024, then fell by 1.35% to $37.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for PRME at $37.4 million in Q4 2025, $35.0 million in Q3 2025, and $34.1 million in Q2 2025.